MP CARDIO-B-NEW's stock price plummeted 5.23% during intraday trading on Tuesday, following the release of its annual financial results.

The company reported that while its revenue for the period ending December 31, 2025, grew by 12.28% year-on-year to $57.044 million, its loss attributable to shareholders expanded significantly to $18.819 million. This represents a 170.85% increase in losses compared to the previous year, with a basic loss per share of $0.04.

The revenue growth was driven by income from the CRM business following a consolidation and rapid overseas expansion of the structural heart disease business. However, investors reacted negatively to the substantial widening of the company's annual losses, leading to the sharp decline in the stock price.